Company Overview and News

0
An arbitration case ‘win’ can be just part of a long legal journey when it comes to Belt and Road

2018-06-03 scmp
Winning an arbitration is a major milestone in the dispute resolution process for a company, but enforcing the award – especially against a state entity in the host nations covered by the Belt and Road Initiative – is often where the bigger challenge lies.
TTML 532371 9437 NTDMF DCM

4
Keysight Technologies, Inc. (KEYS) CEO Ron Nersesian on Q2 2018 Results - Earnings Call Transcript

2018-05-31 seekingalpha
Good day, ladies and gentlemen, and welcome to Keysight Technologies’ Fiscal Second Quarter 2018 Earnings Conference Call. My name is Shawntelle, and I will be your lead operator today. After the presentation, we will conduct a question-and-answer session. [Operator Instructions]. Please note that this call is being recorded today, Wednesday, May 30, 2018 at 1.30 Pacific Time.
DB KEYS 9437 NTDMF DCM

0
Bike-sharing race expected to heat up

2018-05-29 japantimes.co.jp
Bike-sharing service operators are locking horns with each other as the service catches on with consumers.
9437 NTDMF DCM

3
How to lose US$23bil in a market that’s surged 61,436%

2018-05-23 thestar.com.my
The entry of India’s richest man Mukesh Ambani’s Reliance Jio Infocomm Ltd in 2016 has proven to be a turning point in consolidation for the market. — Reuters
532454 9437 NTDMF BHRQY BHARTIARTL DCM

3
How to lose $29 billion in a market that's surged 61,000 per cent

2018-05-23 theage.com.au
Making money in a booming mobile-phone market that soared from fewer than 2 million users to more than a billion in less than two decades might have seemed like a no-brainer.
532454 VOD VOD VODPF 9437 NTDMF BHRQY BHARTIARTL DCM

3
How to lose $29 billion in a market that's surged 61,000 per cent

2018-05-23 smh.com.au
Making money in a booming mobile-phone market that soared from fewer than 2 million users to more than a billion in less than two decades might have seemed like a no-brainer.
532454 VOD VOD VODPF 9437 NTDMF BHRQY BHARTIARTL DCM

0
IIJ Announces Full Year and Fourth Quarter Financial Results for the Fiscal Year Ended March 31, 2018

2018-05-15 globenewswire
TOKYO, May 15, 2018 (GLOBE NEWSWIRE) -- Internet Initiative Japan Inc. ("IIJ") (NASDAQ:IIJI) (TSE:3774) today announced its full year (“FY2017”) and fourth quarter (“4Q17”) consolidated financial results for the fiscal year ended March 31, 2018 (from April 1, 2017 to March 31, 2018).1
3774 CHUEF 9437 NTDMF IIJI IIJIF DCM

12
Synaptics (SYNA) Q3 Earnings Beat, Revenues Miss Estimates

2018-05-10 zacks
Synaptics Incorporated (SYNA - Free Report) delivered third-quarter fiscal 2018 non-GAAP earnings of 92 centsper share that beat the Zacks Consensus Estimate by a couple of cents. The figure also surpassed the mid-point of management’s guided range of 80 cents to $1 per share. However, the figure declined 27.6% from the year-ago quarter.
MRVL PTC SYNA 9437 CTXS NTDMF NTAP DCM

626
Rakuten: An Undervalued, Growing And Diversified Global Business

2018-05-10 seekingalpha
The company is hovering around its 52-week low with a 7.05 EV/EBITDA, after a year that saw 20% YoY revenue growth.
FB SFTBF WMT RKUNF AEOJF YAHOF BABA AMZN AABA 4689 9437 NTDMF YAHOY 9984 RKUNY SFTBY DCM

0
Synaptics (SYNA) Q3 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Good day, everyone, and welcome to the Synaptics Third Quarter Fiscal 2018 Conference Call. Today's call is being recorded.
SYNA 9437 NTDMF DCM

0
NTT DoCoMo's (NTDMF) CEO Kazuhiro Yoshizawa on Q4 2017 Results - Earnings Call Transcript

2018-04-29 seekingalpha
Thank you very much for waiting. We appreciate you taking the time to attend our meeting. From now we would like to start NTT DoCoMo's Results Presentation for the Fiscal Year Ended March 2018 or Fiscal 2017. I am Yoshida [ph] of the IR Department, I'll be serving as your MC today.
9437 NTDMF DCM

0
NTT DOCOMO, Inc. 2017 Q4 - Results - Earnings Call Slides

2018-04-27 seekingalpha
The following slide deck was published by NTT DOCOMO, Inc. in conjunction with their 2017 Q4 earnings call.
9437 NTDMF DCM

0
Nokia Bell Labs and NTT DOCOMO collaborate on 5G innovations for massive capacity, low-latency support of future wireless applications

2018-04-24 globenewswire
Brooklyn 5G Summit, New York, US - Nokia and NTT DOCOMO are collaborating at the Brooklyn 5G Summit to showcase a 5G technology innovation that will deliver massive-capacity to address the increased demand in video data and applications.
9437 NTDMF DCM

0
Japan’s top three mobile carriers to be asked to stop charging customers who switch providers

2018-04-21 japantimes.co.jp
The communications ministry said it will ask Japan’s three top mobile communications carriers to stop charging customers for switching companies when their contracts expire.
9437 NTDMF KDDIF DCM KDDIY

4
REFILE-Rakuten weighs $1.8 bln bond issue to launch mobile service - Nikkei

2018-04-20 reuters
(Reuters) - Japanese e-commerce company Rakuten Inc will issue as much as 200 billion yen ($1.86 billion) to prepare for its entry into the country’s mobile phone service market, the Nikkei business daily reported on Thursday.
9437 NTDMF 9984 SFTBF KDDIF RKUNY RKUNF SFTBY DCM KDDIY

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...